{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T05:26:37Z","timestamp":1767245197093},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/bmt.2013.219","type":"journal-article","created":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T14:51:06Z","timestamp":1389624666000},"page":"492-495","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma"],"prefix":"10.1038","volume":"49","author":[{"given":"W I","family":"Bensinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D J","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Burwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P S","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"BFbmt2013219_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1200\/JCO.2007.11.6863","volume":"26","author":"W Bensinger","year":"2008","unstructured":"Bensinger W . Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008; 26: 480\u2013492.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013219_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E . Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010; 46: 160\u2013169.","journal-title":"Eur J Cancer"},{"key":"BFbmt2013219_CR3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","volume":"28","author":"I Turesson","year":"2010","unstructured":"Turesson I, Velez R, Kristinsson SY, Landgren O . Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010; 28: 830\u2013834.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013219_CR4","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","volume":"101","author":"CM Segeren","year":"2003","unstructured":"Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144\u20132151.","journal-title":"Blood"},{"key":"BFbmt2013219_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/bjh.12123","volume":"160","author":"F Sahebi","year":"2013","unstructured":"Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J et al. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol 2013; 160: 199\u2013206.","journal-title":"Br J Haematol"},{"key":"BFbmt2013219_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.beha.2007.09.007","volume":"20","author":"WI Bensinger","year":"2007","unstructured":"Bensinger WI . Is there still a role for allogeneic stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 783\u2013795.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2013219_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110\u20131120.","journal-title":"N Engl J Med"},{"key":"BFbmt2013219_CR8","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F Garban","year":"2006","unstructured":"Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474\u20133480.","journal-title":"Blood"},{"key":"BFbmt2013219_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E III et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195\u20131203.","journal-title":"Lancet Oncol"},{"key":"BFbmt2013219_CR10","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","volume":"119","author":"HM Lokhorst","year":"2012","unstructured":"Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: 6219\u20136225.","journal-title":"Blood"},{"key":"BFbmt2013219_CR11","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bjorkstrand","year":"2011","unstructured":"Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016\u20133022.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013219_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/sj.bmt.1705393","volume":"37","author":"NW van de Donk","year":"2006","unstructured":"van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1135\u20131141.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013219_CR13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/sj.bmt.1704670","volume":"34","author":"R Zeiser","year":"2004","unstructured":"Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J . Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives (Review). Bone Marrow Transplant 2004; 34: 923\u2013928.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013219_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14712598.2011.554811","volume":"11","author":"C Roddie","year":"2011","unstructured":"Roddie C, Peggs KS . Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation (Review). Expert Opin Biol Ther 2011; 11: 473\u2013487.","journal-title":"Expert Opin Biol Ther"},{"key":"BFbmt2013219_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","volume":"114","author":"P Richardson","year":"2009","unstructured":"Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772\u2013778.","journal-title":"Blood"},{"key":"BFbmt2013219_CR16","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","volume":"118","author":"E Kneppers","year":"2011","unstructured":"Kneppers E, van der HB, Kersten MJ, Zweegman S, Meijer E, Huls G et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118: 2413\u20132419.","journal-title":"Blood"},{"key":"BFbmt2013219_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/leu.2008.247","volume":"23","author":"MC Minnema","year":"2009","unstructured":"Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM . Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23: 605\u2013607.","journal-title":"Leukemia"},{"key":"BFbmt2013219_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3324\/haematol.2012.069328","volume":"98","author":"T Coman","year":"2012","unstructured":"Coman T, Bachy E, Michallet M, Soci\u00e9 G, Uzunov M, Bourhis JH et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the SFGM-TC. Haematologica 2012; 98: 776\u2013783.","journal-title":"Haematologica"},{"key":"BFbmt2013219_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFbmt2013219_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","volume":"41","author":"C Wolschke","year":"2013","unstructured":"Wolschke C, Stubig T, Hegenbart U, Schonland S, Heinzelmann M, Hildebrandt Y et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I\/II dose-finding study. Exp Hematol 2013; 41: 134\u2013142.","journal-title":"Exp Hematol"},{"key":"BFbmt2013219_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.exphem.2012.02.009","volume":"40","author":"J El-Cheikh","year":"2012","unstructured":"El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol 2012; 40: 521\u2013527.","journal-title":"Exp Hematol"},{"key":"BFbmt2013219_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","volume":"37","author":"N Kroger","year":"2009","unstructured":"Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37: 791\u2013798.","journal-title":"Exp Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2013219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:06:28Z","timestamp":1648055188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,13]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFbmt2013219"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.219","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,13]]},"assertion":[{"value":"6 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"William Bensinger received research funding from Celgene for this trial. He has served as an advisor and a speaker for Celgene. Pam Becker has received research funding from Celgene. Nicholas Burwick and Damian Green report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}